Quthero Accepted into Prestigious MaRS-adMare Tx Accelerator

Quthero, a biotech company with a unique, patented Q-peptide platform technology was accepted into the MaRS – adMare Therapeutics (Tx) Accelerator which provides a distinctive ecosystem for the development of novel therapeutics in Ontario and Canada. Quthero’s technology enables and accelerates full regeneration of a patient’s natural tissue with minimal scarring. “”The partnership between MaRS and adMare presents Quthero with a unique opportunity to access the most experienced players in the development of new therapeutics. We are excited to bring our Q-peptide assets to the market in cardio-immunomodulatory therapeutics and dermatology”” said Milica Radisic, PhD, President and CEO of Quthero. Read more >>